Drug Trial Radar · NCT03896009
Maximizing Outcomes in Treating Acute Migraine
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,594
Actual
Start
Mar 4, 2019
Primary completion
Dec 10, 2019
Study completion Dec 10, 2019
Sponsor
- Lead sponsor
- Axsome Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This study is designed to evaluate the efficacy and safety of AXS-07 compared to meloxicam, rizatriptan, and placebo for the treatment of a migraine attack. This is a randomized, double-blind, 4-arm, parallel group, single-dose, placebo-controlled trial. Subjects who successfully complete screening and continue to meet all entry criteria will be randomly assigned to take one dose of either AXS-07, meloxicam, rizatriptan, or placebo upon the occurrence of a qualifying migraine.
Conditions
- Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan)Drug
AXS-07 taken once upon onset of a qualifying migraine.
MeloxicamDrug
Meloxicam taken once upon onset of a qualifying migraine.
RizatriptanDrug
Rizatriptan taken once upon onset of a qualifying migraine.
PlaceboDrug
Placebo taken once upon onset of a qualifying migraine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Reporting Headache Pain FreedomTime frame: Hour 2 following dose administration
- Percentage of Subjects With Absence of Most Bothersome SymptomTime frame: Hour 2 following dose administration
Locations
85 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Mobile, Alabama
Clinical Research Site
Phoenix, Arizona
Clinical Research Site
Tempe, Arizona
Clinical Research Site
Little Rock, Arkansas
Clinical Research Site
Canoga Park, California
Clinical Research Site
Colton, California
Clinical Research Site
Culver City, California
Clinical Research Site
Encino, California
Clinical Research Site
Los Alamitos, California
Clinical Research Site
Los Angeles, California
Clinical Research Site
Oceanside, California
Clinical Research Site
Pomona, California
Clinical Research Site
Redlands, California
Clinical Research Site
Riverside, California
Clinical Research Site
San Diego, California
Clinical Research Site
Santa Monica, California
Clinical Research Site
Spring Valley, California
Clinical Research Site
Walnut Creek, California
Clinical Research Site
Waterbury, Connecticut
Clinical Research Site
Clermont, Florida
Clinical Research Site
DeLand, Florida
Clinical Research Site
Fernandina Beach, Florida
Clinical Research Site
Hallandale, Florida
Clinical Research Site
Hialeah, Florida
Clinical Research Site
Hollywood, Florida
Clinical Research Site
Jacksonville, Florida
Clinical Research Site
Lake City, Florida
Clinical Research Site
Lake Worth, Florida
Clinical Research Site
Miami, Florida
Clinical Research Site
Ocoee, Florida
Clinical Research Site
Orange City, Florida
Clinical Research Site
Orlando, Florida
Clinical Research Site
Ormond Beach, Florida
Clinical Research Site
South Miami, Florida
Clinical Research Site
Sunrise, Florida
Clinical Research Site
Tampa, Florida
Clinical Research Site
Atlanta, Georgia
Clinical Research Site
Atlanta, Georgia
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.